After the UK Prospective Diabetes Study (UKPDS) reported that early intensive glucose control in newly diagnosed type 2 diabetes confers risk reductions for microvascular disease, myocardial infarction, and death that persist for decades after between-group differences in glycated hemoglobin are lost — the 'legacy effect' or metabolic memory — the pathophysiological mechanisms underlying this memory became a central open question. Later work resolved several adjacent uncertainties: the effect persists to 24 years post-trial (UKPDS 91), the metformin subgroup shows no significant microvascular legacy, statistical weighting of historical HbA1c values largely accounts for the mortality/infarction legacy epidemiologically (UKPDS 88), and the effect is contingent on population and endpoint (no macrovascular legacy in ADVANCE-ON or the VA Diabetes Trial, but persistent retinopathy benefit in ACCORDION Eye). What remains open is the biological mechanism: which processes — such as advanced glycation end products, persistent epigenetic modifications, reactive-oxygen-species/protein-kinase-C signaling, or microRNA changes — causally mediate the durable effect of early glycemic exposure on late complications in human tissues. Why the effect is confined to particular populations and outcomes remains unexplained and forms empirical context for the mechanism question.

Background

Glycated hemoglobin (HbA1c) is a standard laboratory measure of average blood-glucose concentration over the preceding ~3 months; in diabetes, lower HbA1c indicates tighter glycemic control. The UK Prospective Diabetes Study (UKPDS) randomized 4209 patients with newly diagnosed type 2 diabetes to intensive glucose-lowering therapy (sulfonylurea — an oral drug class that stimulates pancreatic insulin release — or insulin, or the insulin-sensitizing drug metformin in overweight patients) versus conventional dietary therapy. After the 20-year interventional trial ended, 10 years of post-trial monitoring (UKPDS 80; Holman et al., N Engl J Med 2008) showed that although the difference in HbA1c between groups vanished within a year, risk reductions persisted and even emerged: for sulfonylurea/insulin, a 24% relative reduction in microvascular disease, with emergent 15% and 13% reductions in myocardial infarction and all-cause death; for metformin, persistent 21–33% reductions in any diabetes endpoint, myocardial infarction, and death. This persistence of benefit from a finite period of early tight control was named the 'legacy effect' (Chalmers and Cooper, 2008) and is the type 2 diabetes counterpart of 'metabolic memory' described in type 1 diabetes by the Diabetes Control and Complications Trial (DCCT) and its observational Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up study. The phenomenon is clinically central because it justifies early, tight glycemic control from diagnosis. The UKPDS 80 report itself flagged unresolved issues: the mechanism was unknown, with advanced glycation end products (AGEs — irreversibly glucose-modified proteins that accumulate in vessel walls and alter matrix and cell signaling) and other cumulative intracellular changes proposed but unproven; later follow-up relied on questionnaires and collected no biochemical data after year 5; it was unknown whether the effect generalized to older patients with longer diabetes duration or higher cardiovascular risk, as enrolled in the ADVANCE and ACCORD trials; and the metformin comparison was underpowered for microvascular outcomes. Subsequent trials in higher-risk populations gave sharply different results: ADVANCE-ON (post-trial follow-up of ADVANCE) found no legacy of intensive glucose control on mortality or major macrovascular events, the 15-year Veterans Affairs Diabetes Trial follow-up found no legacy effect at all, while the ACCORDION Eye study found that prior intensive glycemic control continued to reduce retinopathy progression (5.8% vs 12.7%) despite equalized HbA1c — establishing that microvascular memory, but not macrovascular legacy, extends beyond the UKPDS population. Mechanistic hypotheses under investigation include persistent epigenetic modifications (e.g., DNA methylation and histone marks that alter gene expression long after the metabolic stimulus; genome-wide analysis in DCCT/EDIC found DNA methylation differences associated with metabolic memory, but only associationally), AGE accumulation, reactive-oxygen-species production (chemically reactive oxygen byproducts of metabolism that oxidatively damage proteins and DNA) with activation of protein kinase C (a lipid-activated family of intracellular signaling enzymes that alter gene expression and vessel-wall function), and microRNA-mediated pathways (microRNAs are short regulatory RNA molecules that repress gene expression after transcription). As of 2025, reviews still conclude there is no reliable indication of the mechanism by which transient hyperglycemic (or euglycemic) exposure produces a persistent cellular response in target tissues.

Problem Statement

What pathophysiological mechanism(s) underlie the glycemic 'legacy effect' (metabolic memory) observed after early intensive glucose control in newly diagnosed type 2 diabetes — i.e., which molecular or cellular processes (such as advanced glycation end-product accumulation, persistent epigenetic modifications, reactive-oxygen-species/protein-kinase-C signaling, or microRNA-mediated changes) causally mediate the durable risk reductions for microvascular disease, myocardial infarction, and death that persist for decades after between-group HbA1c differences are lost? A complete answer must establish the proposed mediator(s) as causal in humans, not merely associated, distinguishing them from the statistical account (UKPDS 88) in which historical HbA1c values weigh more heavily than recent values in downstream risk. The empirical contingency of the effect across populations and endpoints (no macrovascular or mortality legacy in ADVANCE-ON or the 15-year VADT; persistent retinopathy benefit in ACCORDION Eye) and the metformin-specific endpoint pattern (persistent myocardial-infarction and mortality benefit with no significant microvascular risk reduction in the overweight-only subgroup, per UKPDS 91) form part of the empirical context of the mechanism question.

References

  1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-1589. doi:10.1056/NEJMoa0806470, https://pubmed.ncbi.nlm.nih.gov/18784090/
  2. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med 2008;359(15):1618-1620. doi:10.1056/NEJMe0807625, https://doi.org/10.1056/NEJMe0807625
  3. Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet 2024;404(10448):145-155. doi:10.1016/S0140-6736(24)00537-3, https://pubmed.ncbi.nlm.nih.gov/38772405/
  4. Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care 2021;44(10):2231-2237. doi:10.2337/dc20-2439, https://pubmed.ncbi.nlm.nih.gov/34244332/
  5. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014;371(15):1392-1406. doi:10.1056/NEJMoa1407963, https://pubmed.ncbi.nlm.nih.gov/25234206/
  6. Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, Duckworth WC, Hayward RA; VADT Investigators. Intensive glucose control in patients with type 2 diabetes — 15-year follow-up. N Engl J Med 2019;380(23):2215-2224. doi:10.1056/NEJMoa1806802, https://pubmed.ncbi.nlm.nih.gov/31167051/
  7. Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care 2016;39(7):1089-1100. doi:10.2337/dc16-0024, https://pubmed.ncbi.nlm.nih.gov/27289122/
  8. Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, Wu X, Wang J, Tompkins JD, Genuth S, Braffett BH, Riggs AD; DCCT/EDIC Research Group; Natarajan R. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proc Natl Acad Sci USA 2016;113(21):E3002-E3011. doi:10.1073/pnas.1603712113, https://pubmed.ncbi.nlm.nih.gov/27162351/
  9. Pirola L, Balcerczyk A, Okabe J, El-Osta A. Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 2010;6(12):665-675. doi:10.1038/nrendo.2010.188, https://pubmed.ncbi.nlm.nih.gov/21045787/
  10. Misra A, Bloomgarden Z. Metabolic memory: evolving concepts. J Diabetes 2018;10(3):186-187. doi:10.1111/1753-0407.12622, https://pubmed.ncbi.nlm.nih.gov/29091343/
  11. Cooper ME, El-Osta A, Allen TJ, Watson AMD, Thomas MC, Jandeleit-Dahm KAM. Metabolic karma — the atherogenic legacy of diabetes: the 2017 Edwin Bierman Award Lecture. Diabetes 2018;67(5):785-790. doi:10.2337/dbi18-0010, https://pubmed.ncbi.nlm.nih.gov/29678824/
  12. Lachin JM, Nathan DM, DCCT/EDIC Research Group. Understanding metabolic memory: the prolonged influence of glycemia during the Diabetes Control and Complications Trial (DCCT) on future risks of complications during the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Diabetes Care 2021;44(10):2216-2224. doi:10.2337/dc20-3097, https://pubmed.ncbi.nlm.nih.gov/34548284/
  13. Ahmadi M, Ghafouri-Fard S, Najari-Hanjani P, Morshedzadeh F, Malakoutian T, Abbasi M, Akbari H, Amoli MM, Saffarzadeh N. "Hyperglycemic memory": observational evidence to experimental inference. Curr Diabetes Rev 2025;21(4):64-78. doi:10.2174/0115733998279869231227091944, https://pubmed.ncbi.nlm.nih.gov/38369731/
  14. Rodriguez-Gutierrez R. Legacy effect of intensive glycaemic control in type 2 diabetes — the UKPDS. Lancet 2024;404(10448):100-102. doi:10.1016/S0140-6736(24)01395-3, https://doi.org/10.1016/S0140-6736(24)01395-3